Drastically increase in the healthcare costs, introduction of the customer beneficial insurers and regulators, and emphasizing investor expectations bring to compete to the pharmaceutical manufacturers to create a thorough search for all available sources of revenue. These pressures are emerging globally, with countries seeking a variety of concessions from pharmaceutical manufacturers. In order to launch an effective new drug, the company must account for reduced pricing freedom and a tangle of country and local specific regulations. The best approach of efforts to rationalize regulatory regimes and promote domestic and international trade further contribute to an context in which pharmaceutical manufacturers like Biocon – Syngene manage product launches globally in order to meet expected revenue and profit maximization.